Drug Trial Radar · NCT00448539
Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures
Last checked: Nov 19, 2026Latest source record: Nov 22, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
286
Actual
Start
Mar 15, 2007
Primary completion
May 14, 2010
Study completion May 14, 2010
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- First posted
- Mar 19, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This was an open-label extension study in adolescent and adult (between 12 and 80 years old) participants who had completed their participation in Study E2080-A001-301. The main objective of this study was to evaluate the safety and efficacy of long-term administration of rufinamide for the control of epileptic seizures in participants who had refractory partial seizures despite treatment with a maximum of three approved antiepileptic drugs (AEDs).
Conditions
- Refractory Partial Onset Seizures
Interventions
RufinamideDrug
Dose will be maintained within the range of 2400 to 4800 mg/day (i.e., 1200 to 2400 mg twice daily).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage Change in Total Partial Seizure Frequency Per 28 Days Relative to the Baseline PhaseTime frame: Baseline, Titration Phase (Days 1 to 18), Maintenance Phase
Locations
27 sites in 1 country. Site status is shown where the registry gives one.
University of South Alabama Medical Center
Mobile, Alabama
Clinical Trials, Inc.
Little Rock, Arkansas
Bradenton Research Center
Bradenton, Florida
University of Florida, The Neuroscience Institute at Shands
Jacksonville, Florida
Pediatric Neurologists of Palm Beach
Loxahatchee Groves, Florida
Pediatric Neurosciences, PA
Orlando, Florida
Bay Medical Center
Panama City, Florida
Child Neurology Associates, PC
Atlanta, Georgia
Southern Illinois University Neurology and Pharmacology
Springfield, Illinois
McFarland Clinic PC
Ames, Iowa
John Hopkins Hospital, Dept. of Neurology
Baltimore, Maryland
Hattiesburg Clinic
Hattiesburg, Mississippi
Comprehensive Epilepsy Care Center for Children and Adults
Chesterfield, Missouri
Dartmouth Medical School Neuroscience Center
Lebanon, New Hampshire
Five Towns Neuroscience Research
Cedarhurst, New York
New York University Medical Centre, Comprehensive Epilepsy Center
New York, New York
Weill Cornell Medical Center, Comprehensive Epilepsy Center
New York, New York
Asheville Neurology Specialists
Asheville, North Carolina
Ohio State University
Columbus, Ohio
Medical University of Ohio at Toledo - Dept. of Neurology
Toledo, Ohio
Hospital of The University of Pennsylvania
Philadelphia, Pennsylvania
University of Pennsylvania Medical Center-Department of Neurology
Philadelphia, Pennsylvania
University of Tennessee Health Sciences Center, Dept. of Neurology
Memphis, Tennessee
Access Clinical Trials, Inc
Nashville, Tennessee
Neurological Clinic of Texas, P.A.
Dallas, Texas
Texas Tech University Health Sciences Center, Dept. of Neuropsychiatry
El Paso, Texas
Fletcher Allen Healthcare
Burlington, Vermont
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.